HomeCompareHMTXF vs MO

HMTXF vs MO: Dividend Comparison 2026

HMTXF yields 4072.49% · MO yields 6.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HMTXF wins by $8532781061001.05M in total portfolio value
10 years
HMTXF
HMTXF
● Live price
4072.49%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8532781061001.13M
Annual income
$8,139,610,200,782,360,000.00
Full HMTXF calculator →
MO
Altria Group Inc.
● Live price
6.36%
Share price
$65.99
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80.1K
Annual income
$30,159.17
Full MO calculator →

Portfolio growth — HMTXF vs MO

📍 HMTXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHMTXFMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HMTXF + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HMTXF pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HMTXF
Annual income on $10K today (after 15% tax)
$346,161.68/yr
After 10yr DRIP, annual income (after tax)
$6,918,668,670,665,005,000.00/yr
MO
Annual income on $10K today (after 15% tax)
$540.99/yr
After 10yr DRIP, annual income (after tax)
$25,635.29/yr
At 15% tax rate, HMTXF beats the other by $6,918,668,670,664,979,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HMTXF + MO for your $10,000?

HMTXF: 50%MO: 50%
100% MO50/50100% HMTXF
Portfolio after 10yr
$4266390530500.61M
Annual income
$4,069,805,100,391,194,600.00/yr
Blended yield
95.39%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

HMTXF
No analyst data
Altman Z
-77.1
Piotroski
3/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-7.2% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HMTXF buys
0
MO buys
0
No recent congressional trades found for HMTXF or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHMTXFMO
Forward yield4072.49%6.36%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$8532781061001.13M$80.1K
Annual income after 10y$8,139,610,200,782,360,000.00$30,159.17
Total dividends collected$8505980562203.27M$74.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: HMTXF vs MO ($10,000, DRIP)

YearHMTXF PortfolioHMTXF Income/yrMO PortfolioMO Income/yrGap
1← crossover$417,949$407,249.03$10,570$780.30+$407.4KHMTXF
2$16,354,620$15,907,414.89$11,381$1,032.90+$16.34MHMTXF
3$599,244,865$581,745,420.76$12,535$1,392.73+$599.23MHMTXF
4$20,562,279,794$19,921,087,789.34$14,193$1,920.91+$20562.27MHMTXF
5$660,847,691,261$638,846,051,880.89$16,618$2,723.68+$660847.67MHMTXF
6$19,895,674,352,505$19,188,567,322,855.41$20,263$3,993.80+$19895674.33MHMTXF
7$561,191,767,703,669$539,903,396,146,489.40$25,936$6,098.36+$561191767.68MHMTXF
8$14,833,096,999,026,612$14,232,621,807,583,686.00$35,166$9,775.01+$14833096998.99MHMTXF
9$367,449,402,073,618,800$351,577,988,284,660,350.00$51,026$16,597.78+$367449402073.57MHMTXF
10$8,532,781,061,001,133,000$8,139,610,200,782,360,000.00$80,113$30,159.17+$8532781061001.05MHMTXF

HMTXF vs MO: Complete Analysis 2026

HMTXFStock

Hemostemix Inc., a biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of critical limb ischemia in Canada and the United States, as well as for the treatment of heart and peripheral arterial diseases. The company is also developing various types of cell products, such as synergetic cell populations and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.

Full HMTXF Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this HMTXF vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HMTXF vs SCHDHMTXF vs JEPIHMTXF vs OHMTXF vs KOHMTXF vs MAINHMTXF vs PMHMTXF vs BTIHMTXF vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.